O obxectivo principal do estudo é avaliar a efectividade de nirsevimab na hospitalización polo VRS relacionado con infeccións do tracto respiratorio inferior (ITRI) durante a tempada de VRS (que comeza o 1 de outubro e termina o 1 de marzo) en 3 grupos de nenos: lactantes nados durante a tempada de VRS, lactantes menores de 6 meses ao comezo da tempada de VRS e nenos de alto risco menores de 24 meses ao comezo da tempada de VRS.
Subdirección Xeral
Centro Galego Para O Control E Prevención Das Enfermidades (CEGACE)
Financiación
Descoñecido
Publicacións derivadas
Martinón-Torres F, Mirás-Carballal S, Durán-Parrondo C. Early lessons from
the implementation of universal respiratory syncytial virus prophylaxis in
infants with long-acting monoclonal antibodies, Galicia, Spain, September and
October 2023. Euro Surveill. 2023 Dec;28(49):2300606. doi:
10.2807/1560-7917.ES.2023.28.49.2300606. PMID: 38062942; PMCID: PMC10831408.
the implementation of universal respiratory syncytial virus prophylaxis in
infants with long-acting monoclonal antibodies, Galicia, Spain, September and
October 2023. Euro Surveill. 2023 Dec;28(49):2300606. doi:
10.2807/1560-7917.ES.2023.28.49.2300606. PMID: 38062942; PMCID: PMC10831408.
Ares-Gómez S, Mallah N, Pardo-Seco J, Malvar-Pintos A, Pérez-Martínez O,
Otero-Barrós MT, Súarez-Gaiche N, Santiago-Pérez MI, González-Pérez JM, López-
Pérez LR, Rosón B, Alvárez-Gil RM, Ces-Ozores OM, Nartallo-Penas V, Mirás-
Carballal S, Rodríguez-Tenreiro C, Rivero-Calle I, Salas A, Durán-Parrondo C,
Martinón-Torres F. Short- and mid-term morbidity and primary-care burden due to
infant respiratory syncytial virus infection: A Spanish 6-year population-based
longitudinal study. Pediatr Allergy Immunol. 2024 May;35(5):e14131. doi:
10.1111/pai.14131. PMID: 38700124.
Otero-Barrós MT, Súarez-Gaiche N, Santiago-Pérez MI, González-Pérez JM, López-
Pérez LR, Rosón B, Alvárez-Gil RM, Ces-Ozores OM, Nartallo-Penas V, Mirás-
Carballal S, Rodríguez-Tenreiro C, Rivero-Calle I, Salas A, Durán-Parrondo C,
Martinón-Torres F. Short- and mid-term morbidity and primary-care burden due to
infant respiratory syncytial virus infection: A Spanish 6-year population-based
longitudinal study. Pediatr Allergy Immunol. 2024 May;35(5):e14131. doi:
10.1111/pai.14131. PMID: 38700124.
Mallah N, Ares-Gómez S, Pardo-Seco J, Malvar-Pintos A, Santiago-Pérez MI,
Pérez-Martínez O, Otero-Barrós MT, Suárez-Gaiche N, Kramer R, Jin J, Platero-
Alonso L, Alvárez-Gil RM, Ces-Ozores OM, Nartallo-Penas V, Mirás-Carballal S,
Piñeiro-Sotelo M, González-Pérez JM, Rodríguez-Tenreiro C, Rivero-Calle I, Salas
A, Durán-Parrondo C, Martinón-Torres F. Assessment of effectiveness and impact
of universal prophylaxis with nirsevimab for prevention of hospitalizations due
to respiratory syncytial virus in infants. The NIRSE-GAL study protocol. Hum
Vaccin Immunother. 2024 Dec 31;20(1):2348135. doi:
10.1080/21645515.2024.2348135. Epub 2024 May 13. PMID: 38738683; PMCID:
PMC11093022.
Pérez-Martínez O, Otero-Barrós MT, Suárez-Gaiche N, Kramer R, Jin J, Platero-
Alonso L, Alvárez-Gil RM, Ces-Ozores OM, Nartallo-Penas V, Mirás-Carballal S,
Piñeiro-Sotelo M, González-Pérez JM, Rodríguez-Tenreiro C, Rivero-Calle I, Salas
A, Durán-Parrondo C, Martinón-Torres F. Assessment of effectiveness and impact
of universal prophylaxis with nirsevimab for prevention of hospitalizations due
to respiratory syncytial virus in infants. The NIRSE-GAL study protocol. Hum
Vaccin Immunother. 2024 Dec 31;20(1):2348135. doi:
10.1080/21645515.2024.2348135. Epub 2024 May 13. PMID: 38738683; PMCID:
PMC11093022.
Ares-Gómez S, Mallah N, Santiago-Pérez MI, Pardo-Seco J, Pérez-Martínez O,
Otero-Barrós MT, Suárez-Gaiche N, Kramer R, Jin J, Platero-Alonso L, Alvárez-Gil
RM, Ces-Ozores OM, Nartallo-Penas V, Mirás-Carballal S, Piñeiro-Sotelo M,
Malvar-Pintos A, González-Pérez JM, Rodríguez-Tenreiro-Sánchez C, Rivero-Calle
I, Salas A, Durán-Parrondo C, Martinón-Torres F; NIRSE-GAL study group.
Effectiveness and impact of universal prophylaxis with nirsevimab in infants
against hospitalisation for respiratory syncytial virus in Galicia, Spain:
initial results of a population-based longitudinal study. Lancet Infect Dis.
2024 Aug;24(8):817-828. doi: 10.1016/S1473-3099(24)00215-9. Epub 2024 Apr 30.
Erratum in: Lancet Infect Dis. 2024 Jul;24(7):e419. doi:
10.1016/S1473-3099(24)00355-4. PMID: 38701823.
Otero-Barrós MT, Suárez-Gaiche N, Kramer R, Jin J, Platero-Alonso L, Alvárez-Gil
RM, Ces-Ozores OM, Nartallo-Penas V, Mirás-Carballal S, Piñeiro-Sotelo M,
Malvar-Pintos A, González-Pérez JM, Rodríguez-Tenreiro-Sánchez C, Rivero-Calle
I, Salas A, Durán-Parrondo C, Martinón-Torres F; NIRSE-GAL study group.
Effectiveness and impact of universal prophylaxis with nirsevimab in infants
against hospitalisation for respiratory syncytial virus in Galicia, Spain:
initial results of a population-based longitudinal study. Lancet Infect Dis.
2024 Aug;24(8):817-828. doi: 10.1016/S1473-3099(24)00215-9. Epub 2024 Apr 30.
Erratum in: Lancet Infect Dis. 2024 Jul;24(7):e419. doi:
10.1016/S1473-3099(24)00355-4. PMID: 38701823.
